Remove Gene Editing Remove Gene Therapy Remove Genetics Remove Pharma Companies
article thumbnail

Gene editing: beyond the hype

pharmaphorum

Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Maybe in 50 years’ time we’ll be using gene editing to lower cholesterol, but it won’t replace statins in anyone but those with life threatening mutations for a long time”.

article thumbnail

How epilepsy researchers are moving the needle past anti-seizure treatments

Pharmaceutical Technology

Several biotech companies and researchers are now exploring medical devices and gene therapies to address not just common forms of epilepsy, but also rare conditions such as Dravet Syndrome. In Dravet Syndrome, the approach is to target the SCN1a gene, which has mutations that cause the condition, explains Ferraro.

Research 264
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Life Science Trends to Look Out for in 2024

XTalks

In 2024, pharma companies and emerging biotechs will improve candidate safety profiles and reduce off-target effects by exploiting predictive intelligence unlocked by AI,” she predicts. CRISPR Gene Editing Therapeutics CRISPR/Cas-9 technology makes lists like this almost every year, and for good reason.

article thumbnail

4 Life Sciences Trends for 2023

XTalks

For example, on the pharma and biotech side, there has been growing demand for new drugs and biologics, from new classes of dual-action diabetes and weight loss drugs like Ozempic and Mounjaro to life-saving gene therapies. 1. Cell and Gene Therapies.

article thumbnail

What to expect from drug discovery and development in 2023

Drug Discovery World

As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities. According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2% We are seeing the change from traditional biopharmaceuticals to cell and gene therapies.

article thumbnail

Touchlight boosts DNA manufacturing capacity with latest expansion

Pharmaceutical Technology

Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines.

DNA 130
article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

Dr Salako says there are some clear fields of work associated with different areas, which include: Hertfordshire as a cell and gene therapy hub, with a number of companies in this space clustered around Stevenage. Cambridge is a focal point for many pharmaceutical companies working in this therapeutic area.

Drugs 75